Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity

Abstract

Background and aims

Antiviral therapy (AVT) is required in patients with newly diagnosed hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), if HBV DNA is detectable. We compared the risk of recurrence according to HBV replication activity at the curative treatment of HBV-related HCC.

Methods

Patients with HBV-related HCC who underwent surgical resection or radiofrequency ablation between 2013 and 2018 were enrolled in this retrospective cohort study. Patients were categorized into two groups according to HBV replication activity at the curative treatment of HBV-related HCC (group 1: patients who met the AVT indication for HBV-related HCC due to detectable HBV DNA but did not meet the AVT indication if without HCC; group 2: patients who met the AVT indication, regardless of HCC).

Results

In the entire cohort (n = 911), HCC recurred in 303 (33.3%) patients during a median follow-up of 4.7 years. After multivariate adjustment, group 2 showed a statistically similar risk of HCC recurrence (adjusted hazard ratio [aHR] = 1.18, P = 0.332) compared to that of group 1. In addition, group 2 showed statistically similar risks of early (< 2 years; aHR = 1.31) and late (≥ 2 years; aHR = 0.83) recurrence than that of group 1 (all P>0.05). Propensity score matching and inverse probability of treatment weighting analysis also yielded similar risks of HCC recurrence between the two groups (all P>0.05, log-rank tests).

Conclusions

The risk of HCC recurrence in patients who received curative treatment for newly diagnosed HBV-related HCC was similar regardless of HBV replication activity, if AVT was properly initiated.

Introduction

Hepatitis B virus (HBV) infection is a major risk factor of hepatocellular carcinoma (HCC) [1–4]. The prognosis of patients with HCC remains dismal, with a five-year overall survival of approximately 10 to 15%, as most cases of HCC are still diagnosed at an advanced stage, which precludes curative treatment [5–7]. Ultimately, the cornerstone for improving overall survival lies in the early application of curative treatments, such as transplantation, resection, or radiofrequency ablation (RFA) [8–10].

However, even after curative treatment, the long-term prognosis of patients with HCC is poor, primarily because of its high rate of recurrence (>50% at 5 years) [11, 12]. High HBV DNA levels increase the risk of HCC recurrence after curative treatment [13–16]. Subsequently, it has been demonstrated that suppressing HBV replication with antiviral therapy (AVT) using nucleos(t)ide analogs reduces the risk of HCC recurrence and prolongs survival after curative treatment [17–23]. A previous meta-analysis reported that AVT reduces the risk of HCC recurrence by up to 41% in patients with HBV-related HCC who underwent curative treatment [24].

Recent studies have demonstrated that the prognosis of patients with HBV-related HCC who underwent curative treatment was similar, regardless of the timing of AVT initiation (i.e., initiation before and after HCC treatment) [25, 26], suggesting that prompt AVT initiation is beneficial even after HCC diagnosis to a similar degree as those who initiated AVT before HCC development. Of these patients with detectable HBV DNA, some already fulfilled the AVT indication regardless of HCC diagnosis, while others did not fulfill the AVT indication, if without HCC diagnosis, but received AVT due to detectable HBV DNA. However, it remains unclear whether the impact of AVT on outcomes after curative treatment of HBV-related HCC differs between the two groups with different HBV replication activities at the curative treatment of HCC.

Accordingly, in this large-scale multicenter, retrospective cohort study, we compared the HCC recurrence after curative treatment for HBV-related HCC according to HBV replication activity at the curative treatment of HCC.

Methods

Study subjects

Patients with newly diagnosed HBV-related HCC who received curative treatment (surgical resection or RFA) as the first-line treatment for HCC and those who started AVT using entecavir (ETV) or tenofovir disoproxil fumarate (TDF) as the first-line AVT agent within three months of curative treatment in five academic teaching institutes in South Korea were considered eligible. From January 1, 2013, to December 31, 2018, a total of 4,219 patients were screened.

The exclusion criteria were as follows: (1) age < 19 years, (2) co-infection with hepatitis C virus, (3) decompensated liver cirrhosis (LC), (4) AVT agents other than ETV or TDF, (5) < 6 months of follow-up, (6) HCC recurrence within 6 months, (7) delayed AVT (≥ 3 months after curative treatment), (8) absence of dynamic imaging, and (9) delayed surveillance interval (≥ 7 months) after curative treatment (S1 Fig).

This study received approval from the institutional review boards of all participating institutions (Severance Hospital, Seoul National University Hospital, Kyungpook National University Hospital, and Samsung Medical Center). The study protocol adhered to the ethical guidelines of the 1975 Declaration of Helsinki, and the need for written informed consent was waived due to the retrospective nature of the study. The data were accessed for research purposes from September 11, 2022 to January 11, 2023. Additionally, access to information that could potentially identify individual participants post data collection was secured.

AVT

AVT indication was in accordance with the chronic hepatitis B (CHB) treatment guideline of the Korean Association for the Study of the Liver and reimbursement guideline of the National Health Insurance Service of South Korea during study period (S1 Table) [27, 28]. Briefly, AVT was initiated for CHB patients with (1) HBV DNA ≥20,000 IU/mL for hepatitis B e antigen (HBeAg) positive or HBV DNA ≥2,000 IU/mL for HBeAg negative, and (2) aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2x the upper limit of normal (ULN). For patients with compensated LC, AVT was initiated with (1) HBV DNA ≥2,000 IU/mL, and (2) AST or ALT ≥ 1x ULN before September 1 2015 [27], or regardless of AST or ALT after September 1, 2015 [28–30]. For patients with HCC, AVT was initiated with HBV DNA (≥20 IU/mL) regardless of AST or ALT. The ULN of AST and ALT levels was defined as 40 IU/L, according to the reimbursement criteria of South Korea [31].

Definitions of groups according to HBV replication activity

Patients were categorized into two groups according to HBV replication activity at diagnosis of HCC; group 1 included patients who met only AVT indication for HBV-related HCC (i.e., HBV DNA ≥20 IU/mL and not indicated for AVT if without HCC) and group 2 included those who met AVT indication for CHB regardless of HCC (S2 Fig). The primary reason for not receiving AVT before HCC development, despite meeting AVT indications, were due to inadequate adherence to regular follow-up for CHB. Most patients in group 2 had insufficient follow-up after being diagnosed with CHB. Additionally, some patients were unaware of their CHB diagnosis until the HCC diagnosis. As a result, these patients lacked regular CHB monitoring and missed opportunities for timely AVT initiation.

Diagnosis of HCC and LC

HCC diagnosis was based on histological evidence or radiological findings that included dynamic CT and/or MRI showing typical features of HCC (i.e., nodules >1 cm in size with arterial hypervascularity and portal/delayed-phase washout) [11, 12, 32]. LC was clinically defined as follows: (1) ultrasonographic findings suggestive of cirrhosis, including a blunted, nodular liver surface, and/or (2) esophageal or gastric varices [25].

Study outcomes and follow-up

The primary outcome was HCC recurrence. The same criteria for HCC diagnosis were applied for HCC recurrence. Early HCC recurrence (within 2 years of HCC treatment) and late HCC recurrence (2 years after HCC treatment) were the secondary outcomes [25].

All included patients were followed up with biochemical liver function tests, serum alpha-fetoprotein (AFP) and des-gamma-carboxy-prothrombin (DCP) levels, and imaging with dynamic CT and/or MRI every 3–6 months after curative treatment. No patient underwent adjuvant therapy after surgical resection or RFA during the follow-up period.

Statistical analysis

The baseline characteristics of the study participants were described as mean ± SD or median (interquartile range [IQR]) for continuous variables and as number (percentage) for categorical variables. The distribution of continuous variables was evaluated using the Kolmogorov-Smirnov test. Continuous variables that were not normally distributed were compared using the Mann-Whitney U test, and Student’s t-test was used to compare normally distributed continuous variables. When less than 20% of cells had an expected frequency <5, the chi-square test was used to compare categorical variables; otherwise, Fisher’s exact test was used.

The cumulative risk of HCC recurrence was computed from the index date to the confirmation of recurrence or the date of the last follow-up using the Kaplan–Meier method. The log-rank test was used to compare each group. We conducted the Schoenfeld residual plots and obtained P value from the test to determine if the proportional hazards assumption holds for the groups in the Cox proportional hazards model. Multivariate Cox regression analysis was performed to investigate the independent risks of HCC recurrence according to the groups by calculating adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). The covariates for multivariable adjustment were age, sex, LC, body mass index, diabetes, hypertension, HBeAg positivity, HBV DNA, AST, ALT, albumin, total bilirubin, prothrombin time, platelet count, AFP, DCP, antiviral agent (ETV vs. TDF), tumor number (single vs. multiple), maximal tumor size, and treatment modality (surgical resection vs. RFA).

Furthermore, propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were performed to minimize the effect of potential confounders on the comparison of outcomes between groups. Propensity scores were computed using variables such as age, sex, cirrhosis, body mass index, diabetes, hypertension, antiviral agent, HBeAg, AST, ALT, albumin, total bilirubin, prothrombin time, platelet count, AFP, DCP, tumor number, maximum tumor size, and treatment modality. Outcomes were compared between the groups after adjusting for PSM and IPTW. The IPTW method assigns weights to each individual based on the inverse probability of belonging to their observed group. As a result, when applying IPTW, the effective sample size can differ from the actual number of observed events.

Several sensitivity analyses were performed. The main results were validated according to the AVT indication of the American Association for the Study of the Liver (AASLD) [33], European Association for the Study of the Liver (EASL) [34], and Asia-Pacific Association for the Study of the Liver (APASL) [35] (S1 Table). In addition, we repeated our analysis in each cohort stratified by treatment modality and presence of LC.

All statistical analyses were performed using SAS, version 9.2 (SAS Institute, Cary, NC), R (V.3.0, http://cran.r-project.org/), and IBM SPSS Statistics for Windows, version 26.0 (IBM, Armonk, NY). Two-tailed P values < 0.05 were considered statistically significant.

Results

Baseline characteristics

The baseline characteristics of the study population are summarized in Table 1. Based on our inclusion and exclusion criteria, 911 patients were finally selected for statistical analysis. Of these, 549 (60.3%) and 362 (39.7%) patients belonged to group 1 and group 2, respectively. Patients in group 1 were significantly older (mean 56.7 vs. 54.5 years) and had a significantly lower proportion of cirrhosis (45.5% vs. 56.6%) HBeAg positivity (24.0% vs. 40.9%), lower HBV DNA (median 2.1 vs. 5.3 log₁₀IU/mL), AST (median 32 vs. 39 IU/mL), ALT (median 30 vs. 38 IU/mL), serum albumin (median 4.3 vs. 4.3 g/dL), and AFP levels (median 13.2 vs. 19.0 ng/mL), and a higher proportion of RFA (32.2% vs. 18.5%), than those in the group 2 (all P<0.05). The Albumin-Bilirubin (ALBI) grade for patients was calculated [36]. In total, the proportions of patients according to the ALBI grade were as follows: grade 1, 460 patients (50.5%); grade 2, 425 patients (46.7%); and grade 3, 26 patients (2.9%). There was no significant difference between the groups regarding the proportions of the ALBI grades 2 and 3. The proportions of patients according to the Barcelona Clinic Liver Cancer (BCLC) stages [32, 37, 38] were as follows: stage 0, 227 patients (24.9%); stage A, 599 patients (65.8%); and stage B, 85 patients (9.3%). There was no significant difference between the groups regarding the proportion of BCLC stage B. Among patients who underwent surgical resection, those in the group 1 had a significantly lower proportion of microvascular invasion (42.7% vs. 54.6%) and Edmondson-Stein grades 1 and 2 (48.1% vs. 56.9%) (all P<0.05).

[Figure omitted. See PDF.]

A total of 534 (58.6%), 107 (11.7%), 141 (15.5%), 104 (11.4%), and 2 (2.7%) patients had HBV DNA levels of ≤4.00, 4.01–5.00, 5.01–6.00, 6.01–7.00, and >7 log₁₀IU/mL, respectively (S3 Fig).

Risk of HCC recurrence according to HBV replication activity at the curative treatment

Across the entire cohort, HCC recurred in 303 (33.3%) patients during the follow-up at a median 4.7 (IQR 3.2–5.9) years. Patients with HCC recurrence had a significantly higher proportion of cirrhosis (56.4% vs. 46.7%), diabetes (17.5% vs. 12.3%,), hypertension (26.7% vs. 20.9%), HBeAg positivity (36.3% vs. 28.0%), higher HBV DNA level (median 3.7 vs. 3.3 log₁₀IU/mL), higher AST (median 37 vs. 34 IU/L), higher ALT (median 36 IU/L vs. 32 IU/L), lower serum albumin level (median 4.3 vs. 4.3 g/dL), higher AFP (median 22.7 ng/mL vs. 12.1 ng/mL), higher proportion of multiple tumors (24.7% vs. 13.7%), and higher maximal tumor size (median 2.9 vs. 2.4 cm), compared to those of patients without recurrence (all P<0.05) (S2 Table). In the multivariate analysis, cirrhosis (aHR = 1.28, 95% CI 1.01–1.63), diabetes (aHR = 1.37, 95% CI 1.01–1.87), HBeAg positivity (aHR = 1.48, 95% CI 1.16–1.89), higher AFP level (aHR = 1.00, 95% CI 1.00–1.00), multiple tumors (aHR = 1.49, 95% CI 1.15–1.95), and larger tumor size (aHR = 1.52, 95% CI 1.20–1.93) were independently associated with the increased risk of HCC recurrence (all P<0.05) (S3 Table).

After full adjustment for the key covariates (Model 3), the group 2 did not show a statistically different risk of HCC recurrence, when compared to the group 1 (aHR = 1.18, 95% CI 0.85–1.64; P = 0.332) (Table 2). We assessed the proportional hazards assumption to ensure the validity of our Cox proportional hazards model. Based on the Schoenfeld residual test, the group 1 satisfied Cox proportional hazard assumption for the risk of HCC recurrence (P = 0.069 compared to the group 2).

[Figure omitted. See PDF.]

PSM and IPTW adjustment

The baseline characteristics of groups 1 and 2 after PSM and IPTW adjustment are shown in Table 3. All parameters were well balanced (all P>0.05). In PSM analysis with 321 pairs, the cumulative probabilities of HCC recurrence at 1, 3, and 5 years were 11.7%, 27.3%, and 37.9% (incidence rate 11.9 per 100 person-years), respectively in the group 1, and 15.0%, 32.8%, and 39.8% (incidence rate 12.3 per 100 person-years), respectively, in the group 2, without significant difference (P = 0.565; Fig 1A). Similarly, in the IPTW analysis, similar risk of HCC recurrence was observed between the two groups (P = 0.378) (Fig 1B).

[Figure omitted. See PDF.]

A, HCC recurrence after propensity score matching adjustment; B, HCC recurrence after inverse probability of treatment weighting adjustment. HCC, hepatocellular carcinoma.

[Figure omitted. See PDF.]

When compared to the group 1 as the reference, the HR of the group 2 for HCC recurrence was 1.13 (95% CI 0.87–1.46; P = 0.376), indicating no statistical difference between the two groups (Table 4).

[Figure omitted. See PDF.]

Risk of early and late HCC recurrence according to HBV replication activity at the curative treatment

In the entire cohort, 101 patients in the group 1 and 97 patients in the group 2 developed early HCC recurrence. After full adjustment (Model 3), the group 2 did not show a statistically different risk of early HCC recurrence, when compared to the group 1 (aHR = 1.31, 95% CI: 0.88–1.95; P = 0.187) (Table 2). In addition, 60 patients in the group 1 and 45 in the group 2 developed late HCC recurrence. After full adjustment (Model 3), the group 2 did not show a statistically different cumulative risks of late HCC recurrence compared to the group 1 (aHR = 0.83, 95% CI: 0.45–1.55; P = 0.562) (Table 2).

Similar results were reproduced in PSM and IPTW analyses. The cumulative probabilities of early and late HCC recurrence did not differ between the two groups: (P = 0.094) for early recurrence (Fig 2A) and (P = 0.109) for late recurrence (Fig 2B) on PSM, and (P = 0.099) for early recurrence (Fig 2C) and (P = 0.195) for late recurrence (Fig 2D) on IPTW. When compare to the group 1 as the reference, the HRs were 1.31 (95% CI 0.95–1.80; P = 0.095) for early recurrence and 0.76 (95% CI 0.50–1.15; P = 0.196) for late recurrence, indicating no statistical difference between the two groups (Table 4).

[Figure omitted. See PDF.]

A, early HCC recurrence after propensity score matching adjustment; B, late HCC recurrence after propensity score matching adjustment; C, early HCC recurrence after inverse probability of treatment weighting adjustment; D, late HCC recurrence after inverse probability of treatment weighting adjustment. HCC, hepatocellular carcinoma.

Sensitivity analyses

When the pathological findings were further matched among patients who underwent surgical resection (S4 Table), the risk of HCC recurrence, early recurrence, and late recurrence were statistically similar between the two groups (all P>0.05) (S5 Table).

When patients were categorized into groups 1 and 2 according to the AASLD, EASL, and APASL guidelines (S1 Table), the risks of HCC recurrence, early recurrence, and late recurrence were statistically similar between the two groups (all P>0.05) (S6 Table). In addition, when the patients were divided into two groups with surgical resection and RFA or with cirrhosis and non-cirrhosis, the risk of HCC recurrence, early recurrence, and late recurrence were statistically similar between the two groups (all P>0.05) (S7 and S8 Tables).

Discussion

In this multicenter, large-scale cohort study, we found that the risk of HCC recurrence was comparable between the groups categorized by HBV replication activity at the curative treatment of HCC (group 1, patients who met only AVT indication for HBV-related HCC and not indicated for AVT if without HCC, vs. group 2, those who met AVT indication for CHB regardless of HCC) if AVT was properly initiated. Furthermore, the risk of early and late HCC recurrence was also comparable between the groups. These outcomes were reproduced using the Cox regression, PSM, and IPTW analyses.

Persistent HBV replication is a major risk predictor of HCC recurrence after curative surgical resection [14, 39, 40] and RFA [15, 16, 41] in patients with HBV-related HCC who have not received AVT. In a nationwide cohort study from Taiwan involving 4,569 patients with HBV-related HCC who underwent curative liver resections, AVT significantly reduced the risk of HCC recurrence (HR = 0.67), even in patients with a low viral load (HBV DNA level <2,000 IU/mL) [42]. The benefit of AVT in decreasing HCC recurrence has also been observed after RFA [22, 23]. Several meta-analyses have demonstrated that the risk of HCC recurrence and overall mortality after curative treatment is reduced by approximately 40% and 40–70%, respectively [24, 43, 44]. All these studies indicate that effective suppression of HBV replication is crucial for reducing HCC recurrence and improving overall survival in patients with HBV-related HCC, even after curative treatment. However, the efficacy of AVT after curative treatment for HBV-related HCC according to HBV replication activity remains unclear.

Our study has several strengths. First, to the best of our knowledge, our study is the first report on the direct comparison of long-term outcomes of AVT according to HBV replication activity, that is, fulfilment of AVT indication only with HCC at the curative treatment and fulfillment of AVT indication at the curative treatment. We directly compared the efficacy according to the different fulfillment of AVT indication of potent AVT, EVT, and TDF on HCC recurrence after curative treatment.

Second, based on our large cohort size (approximately 900 patients), we were able to separately explore the efficacy of AVT between the two groups for the prevention of early and late recurrence as the secondary outcome. It is generally known that most early recurrence within 2 years of curative treatment results from occult metastasis from the primary tumor [45], whereas late recurrence after 2 years of curative treatment is a de novo second primary tumor spontaneously arising in the remaining liver [46, 47]. The observation that the risk of early recurrence is comparable between the two groups demonstrated that the efficacy of AVT on prevention of HCC recurrence was not influenced by factors associated with tumors and/or treatments. More importantly, since late recurrence is associated with underlying liver conditions, such as cirrhosis and/or active HBV replication [48, 49], our findings imply that AVT can similarly prevent HCC recurrence, even in the high-risk late recurrence group.

Third, our data from real-life cohorts, with a relatively large sample of 911 patients from five independent tertiary academic teaching hospitals, enables the applicability of our findings to routine clinical practice. Furthermore, the number of cases in our cohort, including 303 (33.3%) HCCs during the median follow-up period of 4.7 years ensured statistical reliability. Subgroup analyses using various stratifications demonstrated the robustness of the results. The similarity in outcomes between the two groups was consistent regardless of the recurrence type (early or late), HCC treatment modality (surgical resection or RFA), or the presence of cirrhosis.

Fourth, owing to the potential selection bias in our study, the baseline characteristics that can impact HCC recurrence, including age, sex, cirrhosis, HBV DNA level, were significantly different between groups. Thus, we applied stringent statistical approaches using multivariable adjustment with PSM and IPTW analyses to adjust for these differences. Specifically, in patients who underwent surgical resection, we adjusted for pathological variables that are well-known as risk factors for recurrence, such as portal vein invasion, microvascular invasion, and tumor differentiation [50]. Even after matching, we found the consistent results between patients who underwent surgical resection and those from the entire cohort.

Despite its clinical implications, our study has several limitations. First, although we attempted to overcome the nature of the retrospective design by using several strategies of statistical matching, unmeasured bias and confounding factors could not be avoided. Second, given that this was a multicenter study, variations relative to the techniques of surgery and RFA, and post-treatment care techniques might have occurred across the centers. Finally, our results may not be generalizable to patients of other ethnicities with CHB, as most patients with CHB infection in South Korea have genotype C HBV acquired through vertical transmission.

In conclusion, the risk of HCC recurrence in patients who received curative treatment for newly diagnosed HBV-related HCC was similar regardless of HBV replication activity, if AVT was properly initiated. Thus, although HBV replication activity was not appropriately controlled, initiation of AVT using highly potent agents after curative treatment of HBV-related HCC may be sufficient to reduce the risk of HCC recurrence.

Supporting information

S1 Fig. Study flow diagram.

HCC, hepatocellular carcinoma; ETV, entecavir; TDF, tenofovir disoproxil fumarate; AVT, antiviral therapy.

https://doi.org/10.1371/journal.pone.0307712.s001

S2 Fig. Definitions of group 1 & 2 according to HBV replication activity.

HBV, hepatitis B virus.

https://doi.org/10.1371/journal.pone.0307712.s002

S3 Fig. Proportion of patients in each HBV DNA category at enrollment.

https://doi.org/10.1371/journal.pone.0307712.s003

S1 Table. Indication of antiviral therapy in each guideline.

https://doi.org/10.1371/journal.pone.0307712.s004

(DOCX)

S2 Table. Comparison between patients who developed HCC recurrence and those who did not.

https://doi.org/10.1371/journal.pone.0307712.s005

(DOCX)

S3 Table. Independent predictors of HCC recurrence.

https://doi.org/10.1371/journal.pone.0307712.s006

(DOCX)

S4 Table. Baseline characteristics of groups 1 and 2 after PSM and IPTW adjustment in patients receiving surgical resection.

https://doi.org/10.1371/journal.pone.0307712.s007

(DOCX)

S5 Table. The risk of HCC recurrence and mortality according to the groups in patients receiving surgical resection after PSM and IPTW adjustment.

https://doi.org/10.1371/journal.pone.0307712.s008

(DOCX)

S6 Table. The risk of HCC recurrence, early recurrence, and late recurrence according to the groups (defined by AASLD, EASL, and APASL guidelines).

https://doi.org/10.1371/journal.pone.0307712.s009

(DOCX)

S7 Table. The risk of HCC recurrence, early recurrence, and late recurrence according to the groups in each treatment modality (surgical resection and RFA).

https://doi.org/10.1371/journal.pone.0307712.s010

(DOCX)

S8 Table. The risk of HCC recurrence, early recurrence, and late recurrence according to the groups in each cohort of cirrhosis and non-cirrhosis.

https://doi.org/10.1371/journal.pone.0307712.s011

(DOCX)

References

1. 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. Epub 20210204. pmid:33538338.

* View Article

* PubMed/NCBI

* Google Scholar

2. 2. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer. 2019;144(8):1941–53. Epub 2018/10/24. pmid:30350310.

* View Article

* PubMed/NCBI

* Google Scholar

3. 3. Lee HW, Kim M, Youn J, Singh S, Ahn SH. Liver Diseases in South Korea: A Pulse Check of the Public’s Knowledge, Awareness, and Behaviors. Yonsei Med J. 2022;63(12):1088–98. pmid:36444544; PubMed Central PMCID: PMC9760893.

* View Article

* PubMed/NCBI

* Google Scholar

4. 4. Bertoletti A, Tan AT. Engineering HBV-specific T cells for treatment of HBV-related HCC and HBV infection: past, present and future. Clin Mol Hepatol. 2024. Epub 20240627. pmid:38934109.

* View Article

* PubMed/NCBI

* Google Scholar

5. 5. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE—5-a population-based study. The Lancet Oncology. 2014;15(1):23–34. Epub 2013/12/10. pmid:24314615.

* View Article

* PubMed/NCBI

* Google Scholar

6. 6. Xie D, Shi J, Zhou J, Fan J, Gao Q. Clinical practice guideline and real-life practice in hepatocellular carcinoma: Chinese perspective. Clinical and molecular hepatology. 2022. Epub 2022/12/23. pmid:36545708.

* View Article

* PubMed/NCBI

* Google Scholar

7. 7. Yu JH, Cho SG, Jin YJ, Lee JW. The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection. Clinical and molecular hepatology. 2022;28(3):351–61. Epub 2021/11/26. pmid:34823308; PubMed Central PMCID: PMC9293610.

* View Article

* PubMed/NCBI

* Google Scholar

8. 8. Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150(4):835–53. Epub 2016/01/23. pmid:26795574.

* View Article

* PubMed/NCBI

* Google Scholar

9. 9. Sankar K, Gong J, Osipov A, Miles SA, Kosari K, Nissen NN, et al. Recent advances in the management of hepatocellular carcinoma. Clinical and molecular hepatology. 2024;30(1):1–15. Epub 20230721. pmid:37482076; PubMed Central PMCID: PMC10776289.

* View Article

* PubMed/NCBI

* Google Scholar

10. 10. Bae H, Lee SA, Choi JW, Hwang SH, Park S, Park MS. Effectiveness of Hepatocellular Carcinoma Surveillance and an Optimal Surveillance Interval: Nationwide Cohort of Korea. Yonsei Med J. 2021;62(8):758–66. pmid:34296554; PubMed Central PMCID: PMC8298874.

* View Article

* PubMed/NCBI

* Google Scholar

11. 11. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of hepatology. 2018;69(1):182–236. Epub 2018/04/10. pmid:29628281.

* View Article

* PubMed/NCBI

* Google Scholar

12. 12. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md). 2018;67(1):358–80. Epub 2017/01/29. pmid:28130846.

* View Article

* PubMed/NCBI

* Google Scholar

13. 13. Kim BK, Park JY, Kim DY, Kim JK, Kim KS, Choi JS, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver international: official journal of the International Association for the Study of the Liver. 2008;28(3):393–401. Epub 2007/11/22. pmid:18028321.

* View Article

* PubMed/NCBI

* Google Scholar

14. 14. Yang T, Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol. 2012;38(8):683–91. Epub 20120522. pmid:22621971.

* View Article

* PubMed/NCBI

* Google Scholar

15. 15. Xia F, Lai EC, Lau WY, Ma K, Li X, Bie P, et al. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma. Annals of surgical oncology. 2012;19(4):1284–91. Epub 2011/09/14. pmid:21913016.

* View Article

* PubMed/NCBI

* Google Scholar

16. 16. Sohn W, Paik YH, Lee MW, Rhim H, Lim HK, Cho JY, et al. Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma after percutaneous radiofrequency ablation. Scand J Gastroenterol. 2014;49(3):373–80. Epub 20131219. pmid:24354931.

* View Article

* PubMed/NCBI

* Google Scholar

17. 17. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. Jama. 2012;308(18):1906–14. Epub 2012/11/20. pmid:23162861.

* View Article

* PubMed/NCBI

* Google Scholar

18. 18. Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013;31(29):3647–55. Epub 2013/09/05. pmid:24002499.

* View Article

* PubMed/NCBI

* Google Scholar

19. 19. Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg. 2015;261(1):56–66. Epub 2014/07/30. pmid:25072444.

* View Article

* PubMed/NCBI

* Google Scholar

20. 20. Wong GL, Tse YK, Chan HL, Yip TC, Tsoi KK, Wong VW. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2016;43(7):802–13. Epub 2016/02/05. pmid:26843444.

* View Article

* PubMed/NCBI

* Google Scholar

21. 21. Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. Journal of hepatology. 2013;58(1):89–97. Epub 2012/10/02. pmid:23023009.

* View Article

* PubMed/NCBI

* Google Scholar

22. 22. Lee TY, Lin JT, Zeng YS, Chen YJ, Wu MS, Wu CY. Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation. Hepatology (Baltimore, Md). 2016;63(5):1517–27. Epub 2015/10/02. pmid:26426978.

* View Article

* PubMed/NCBI

* Google Scholar

23. 23. Sohn W, Kang TW, Choi SK, Jung SH, Lee MW, Lim HK, et al. Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget. 2016;7(30):47794–807. Epub 2016/06/23. pmid:27329596; PubMed Central PMCID: PMC5216979.

* View Article

* PubMed/NCBI

* Google Scholar

24. 24. Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Alimentary pharmacology & therapeutics. 2011;33(10):1104–12. Epub 2011/04/15. pmid:21488914.

* View Article

* PubMed/NCBI

* Google Scholar

25. 25. Kim MN, Kim BK, Roh YH, Choi NR, Yu SJ, Kim SU. Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2022;20(8):1877–80.e3. Epub 20220215. pmid:35181566.

* View Article

* PubMed/NCBI

* Google Scholar

26. 26. Hui VW, Chan SL, Wong VW, Liang LY, Yip TC, Lai JC, et al. Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. JHEP reports: innovation in hepatology. 2020;2(6):100152. Epub 2020/10/08. pmid:33024950; PubMed Central PMCID: PMC7530304.

* View Article

* PubMed/NCBI

* Google Scholar

27. 27. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clinical and molecular hepatology. 2012;18(2):109–62. Epub 2012/08/16. pmid:22893865; PubMed Central PMCID: PMC3415874.

* View Article

* PubMed/NCBI

* Google Scholar

28. 28. KASL clinical practice guidelines: management of chronic hepatitis B. Clinical and molecular hepatology. 2016;22(1):18–75. Epub 2016/04/06. pmid:27044762; PubMed Central PMCID: PMC4825166.

* View Article

* PubMed/NCBI

* Google Scholar

29. 29. KASL clinical practice guidelines for management of chronic hepatitis B. Clinical and molecular hepatology. 2019;25(2):93–159. Epub 2019/06/13. pmid:31185710; PubMed Central PMCID: PMC6589848.

* View Article

* PubMed/NCBI

* Google Scholar

30. 30. http://www.mohw.go.kr/react/jb/sjb0406vw.jsp?PAR_MENU_ID=03&MENU_ID=030406&CONT_SEQ=325094&page=1.

31. 31. https://www.hira.or.kr/rd/insuadtcrtr/InsuAdtCrtrList.do?pgmid=HIRAA030069000000.

32. 32. Cho Y, Kim BH, Park JW. Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison. Clin Mol Hepatol. 2023;29(2):252–62. Epub 20230310. pmid:36907570; PubMed Central PMCID: PMC10121305.

* View Article

* PubMed/NCBI

* Google Scholar

33. 33. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99. Epub 2018/02/07. pmid:29405329; PubMed Central PMCID: PMC5975958.

* View Article

* PubMed/NCBI

* Google Scholar

34. 34. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98. Epub 20170418. pmid:28427875.

* View Article

* PubMed/NCBI

* Google Scholar

35. 35. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. Epub 20151113. pmid:26563120; PubMed Central PMCID: PMC4722087.

* View Article

* PubMed/NCBI

* Google Scholar

36. 36. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–8. Epub 20141215. pmid:25512453; PubMed Central PMCID: PMC4322258.

* View Article

* PubMed/NCBI

* Google Scholar

37. 37. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681–93. Epub 20211119. pmid:34801630; PubMed Central PMCID: PMC8866082.

* View Article

* PubMed/NCBI

* Google Scholar

38. 38. Goh MJ, Sinn DH, Kim JM, Lee MW, Hyun DH, Yu JI, et al. Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective. Clin Mol Hepatol. 2023;29(2):197–205. Epub 20230105. pmid:36603575; PubMed Central PMCID: PMC10121294.

* View Article

* PubMed/NCBI

* Google Scholar

39. 39. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. The American journal of gastroenterology. 2008;103(7):1663–73. Epub 2008/07/12. pmid:18616655.

* View Article

* PubMed/NCBI

* Google Scholar

40. 40. Qu LS, Jin F, Huang XW, Shen XZ. High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2010;14(7):1111–20. Epub 2010/04/28. pmid:20422305.

* View Article

* PubMed/NCBI

* Google Scholar

41. 41. Goto T, Yoshida H, Tateishi R, Enooku K, Goto E, Sato T, et al. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatology international. 2011;5(3):767–73. Epub 2011/04/13. pmid:21484129.

* View Article

* PubMed/NCBI

* Google Scholar

42. 42. Liu KX, Hong JG, Wu R, Dong ZR, Yang YF, Yan YC, et al. Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis. Frontiers in oncology. 2021;11:605648. Epub 2021/03/09. pmid:33680960; PubMed Central PMCID: PMC7933452.

* View Article

* PubMed/NCBI

* Google Scholar

43. 43. Sun P, Dong X, Cheng X, Hu Q, Zheng Q. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. PloS one. 2014;9(7):e102761. Epub 2014/07/25. pmid:25058587; PubMed Central PMCID: PMC4109946.

* View Article

* PubMed/NCBI

* Google Scholar

44. 44. Liu GM, Huang XY, Shen SL, Hu WJ, Peng BG. Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis. Hepatology research: the official journal of the Japan Society of Hepatology. 2016;46(1):100–10. Epub 2015/09/04. pmid:26331530.

* View Article

* PubMed/NCBI

* Google Scholar

45. 45. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51(5):890–7. Epub 20090723. pmid:19747749.

* View Article

* PubMed/NCBI

* Google Scholar

46. 46. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. Journal of hepatology. 2003;38(2):200–7. Epub 2003/01/28. pmid:12547409.

* View Article

* PubMed/NCBI

* Google Scholar

47. 47. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89(3):500–7. Epub 2000/08/10. pmid:10931448.

* View Article

* PubMed/NCBI

* Google Scholar

48. 48. Zheng J, Chou JF, Gönen M, Vachharajani N, Chapman WC, Majella Doyle MB, et al. Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort. Annals of surgery. 2017;266(4):693–701. Epub 2017/06/27. pmid:28650354; PubMed Central PMCID: PMC8404085.

* View Article

* PubMed/NCBI

* Google Scholar

49. 49. Poon RT. Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol. 2009;16(4):792–4. Epub 20090204. pmid:19190964.

* View Article

* PubMed/NCBI

* Google Scholar

50. 50. Ivanics T, Murillo Perez CF, Claasen M, Patel MS, Morgenshtern G, Erdman L, et al. Dynamic risk profiling of HCC recurrence after curative intent liver resection. Hepatology (Baltimore, Md). 2022;76(5):1291–301. Epub 2022/02/19. pmid:35178739.

* View Article

* PubMed/NCBI

* Google Scholar

Citation: Kim MN, Kim BK, Cho H, Goh MJ, Roh YH, Yu SJ, et al. (2024) Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity. PLoS ONE 19(8): e0307712. https://doi.org/10.1371/journal.pone.0307712

About the Authors:

Mi Na Kim

Roles: Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing

¶‡ MNK and BKK contributed equally as first authors. SJY, DHS, SYP and SUK equally contributed equally as corresponding authors.

Affiliations: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea, Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea

Beom Kyung Kim

Roles: Conceptualization, Formal analysis, Writing – review & editing

¶‡ MNK and BKK contributed equally as first authors. SJY, DHS, SYP and SUK equally contributed equally as corresponding authors.

Affiliations: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea, Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea

Heejin Cho

Roles: Data curation

Affiliation: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

Myung Ji Goh

Roles: Data curation

Affiliation: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Yun Ho Roh

Roles: Formal analysis

Affiliation: Biostatistics Collaboration Unit, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea

Su Jong Yu

Roles: Data curation, Supervision, Writing – review & editing

E-mail: [email protected] (SUK); [email protected] (SYP); [email protected] (DHS); [email protected] (SJY)

¶‡ MNK and BKK contributed equally as first authors. SJY, DHS, SYP and SUK equally contributed equally as corresponding authors.

Affiliation: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

Dong Hyun Sinn

Roles: Data curation, Supervision, Writing – review & editing

E-mail: [email protected] (SUK); [email protected] (SYP); [email protected] (DHS); [email protected] (SJY)

¶‡ MNK and BKK contributed equally as first authors. SJY, DHS, SYP and SUK equally contributed equally as corresponding authors.

Affiliation: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Soo Young Park

Roles: Conceptualization, Data curation, Supervision, Writing – review & editing

E-mail: [email protected] (SUK); [email protected] (SYP); [email protected] (DHS); [email protected] (SJY)

¶‡ MNK and BKK contributed equally as first authors. SJY, DHS, SYP and SUK equally contributed equally as corresponding authors.

Affiliation: Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea

Seung Up Kim

Roles: Conceptualization, Formal analysis, Supervision, Writing – review & editing

E-mail: [email protected] (SUK); [email protected] (SYP); [email protected] (DHS); [email protected] (SJY)

¶‡ MNK and BKK contributed equally as first authors. SJY, DHS, SYP and SUK equally contributed equally as corresponding authors.

Affiliations: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea, Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea

ORICD: https://orcid.org/0000-0002-9658-8050

[/RAW_REF_TEXT]

[/RAW_REF_TEXT]

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. Epub 20210204. pmid:33538338.

2. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer. 2019;144(8):1941–53. Epub 2018/10/24. pmid:30350310.

3. Lee HW, Kim M, Youn J, Singh S, Ahn SH. Liver Diseases in South Korea: A Pulse Check of the Public’s Knowledge, Awareness, and Behaviors. Yonsei Med J. 2022;63(12):1088–98. pmid:36444544; PubMed Central PMCID: PMC9760893.

4. Bertoletti A, Tan AT. Engineering HBV-specific T cells for treatment of HBV-related HCC and HBV infection: past, present and future. Clin Mol Hepatol. 2024. Epub 20240627. pmid:38934109.

5. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE—5-a population-based study. The Lancet Oncology. 2014;15(1):23–34. Epub 2013/12/10. pmid:24314615.

6. Xie D, Shi J, Zhou J, Fan J, Gao Q. Clinical practice guideline and real-life practice in hepatocellular carcinoma: Chinese perspective. Clinical and molecular hepatology. 2022. Epub 2022/12/23. pmid:36545708.

7. Yu JH, Cho SG, Jin YJ, Lee JW. The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection. Clinical and molecular hepatology. 2022;28(3):351–61. Epub 2021/11/26. pmid:34823308; PubMed Central PMCID: PMC9293610.

8. Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150(4):835–53. Epub 2016/01/23. pmid:26795574.

9. Sankar K, Gong J, Osipov A, Miles SA, Kosari K, Nissen NN, et al. Recent advances in the management of hepatocellular carcinoma. Clinical and molecular hepatology. 2024;30(1):1–15. Epub 20230721. pmid:37482076; PubMed Central PMCID: PMC10776289.

10. Bae H, Lee SA, Choi JW, Hwang SH, Park S, Park MS. Effectiveness of Hepatocellular Carcinoma Surveillance and an Optimal Surveillance Interval: Nationwide Cohort of Korea. Yonsei Med J. 2021;62(8):758–66. pmid:34296554; PubMed Central PMCID: PMC8298874.

11. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of hepatology. 2018;69(1):182–236. Epub 2018/04/10. pmid:29628281.

12. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md). 2018;67(1):358–80. Epub 2017/01/29. pmid:28130846.

13. Kim BK, Park JY, Kim DY, Kim JK, Kim KS, Choi JS, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver international: official journal of the International Association for the Study of the Liver. 2008;28(3):393–401. Epub 2007/11/22. pmid:18028321.

14. Yang T, Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol. 2012;38(8):683–91. Epub 20120522. pmid:22621971.

15. Xia F, Lai EC, Lau WY, Ma K, Li X, Bie P, et al. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma. Annals of surgical oncology. 2012;19(4):1284–91. Epub 2011/09/14. pmid:21913016.

16. Sohn W, Paik YH, Lee MW, Rhim H, Lim HK, Cho JY, et al. Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma after percutaneous radiofrequency ablation. Scand J Gastroenterol. 2014;49(3):373–80. Epub 20131219. pmid:24354931.

17. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. Jama. 2012;308(18):1906–14. Epub 2012/11/20. pmid:23162861.

18. Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013;31(29):3647–55. Epub 2013/09/05. pmid:24002499.

19. Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg. 2015;261(1):56–66. Epub 2014/07/30. pmid:25072444.

20. Wong GL, Tse YK, Chan HL, Yip TC, Tsoi KK, Wong VW. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2016;43(7):802–13. Epub 2016/02/05. pmid:26843444.

21. Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. Journal of hepatology. 2013;58(1):89–97. Epub 2012/10/02. pmid:23023009.

22. Lee TY, Lin JT, Zeng YS, Chen YJ, Wu MS, Wu CY. Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation. Hepatology (Baltimore, Md). 2016;63(5):1517–27. Epub 2015/10/02. pmid:26426978.

23. Sohn W, Kang TW, Choi SK, Jung SH, Lee MW, Lim HK, et al. Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget. 2016;7(30):47794–807. Epub 2016/06/23. pmid:27329596; PubMed Central PMCID: PMC5216979.

24. Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Alimentary pharmacology & therapeutics. 2011;33(10):1104–12. Epub 2011/04/15. pmid:21488914.

25. Kim MN, Kim BK, Roh YH, Choi NR, Yu SJ, Kim SU. Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2022;20(8):1877–80.e3. Epub 20220215. pmid:35181566.

26. Hui VW, Chan SL, Wong VW, Liang LY, Yip TC, Lai JC, et al. Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. JHEP reports: innovation in hepatology. 2020;2(6):100152. Epub 2020/10/08. pmid:33024950; PubMed Central PMCID: PMC7530304.

27. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clinical and molecular hepatology. 2012;18(2):109–62. Epub 2012/08/16. pmid:22893865; PubMed Central PMCID: PMC3415874.

28. KASL clinical practice guidelines: management of chronic hepatitis B. Clinical and molecular hepatology. 2016;22(1):18–75. Epub 2016/04/06. pmid:27044762; PubMed Central PMCID: PMC4825166.

29. KASL clinical practice guidelines for management of chronic hepatitis B. Clinical and molecular hepatology. 2019;25(2):93–159. Epub 2019/06/13. pmid:31185710; PubMed Central PMCID: PMC6589848.

30. http://www.mohw.go.kr/react/jb/sjb0406vw.jsp?PAR_MENU_ID=03&MENU_ID=030406&CONT_SEQ=325094&page=1.

31. https://www.hira.or.kr/rd/insuadtcrtr/InsuAdtCrtrList.do?pgmid=HIRAA030069000000.

32. Cho Y, Kim BH, Park JW. Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison. Clin Mol Hepatol. 2023;29(2):252–62. Epub 20230310. pmid:36907570; PubMed Central PMCID: PMC10121305.

33. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99. Epub 2018/02/07. pmid:29405329; PubMed Central PMCID: PMC5975958.

34. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98. Epub 20170418. pmid:28427875.

35. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. Epub 20151113. pmid:26563120; PubMed Central PMCID: PMC4722087.

36. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–8. Epub 20141215. pmid:25512453; PubMed Central PMCID: PMC4322258.

37. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681–93. Epub 20211119. pmid:34801630; PubMed Central PMCID: PMC8866082.

38. Goh MJ, Sinn DH, Kim JM, Lee MW, Hyun DH, Yu JI, et al. Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective. Clin Mol Hepatol. 2023;29(2):197–205. Epub 20230105. pmid:36603575; PubMed Central PMCID: PMC10121294.

39. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. The American journal of gastroenterology. 2008;103(7):1663–73. Epub 2008/07/12. pmid:18616655.

40. Qu LS, Jin F, Huang XW, Shen XZ. High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2010;14(7):1111–20. Epub 2010/04/28. pmid:20422305.

41. Goto T, Yoshida H, Tateishi R, Enooku K, Goto E, Sato T, et al. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatology international. 2011;5(3):767–73. Epub 2011/04/13. pmid:21484129.

42. Liu KX, Hong JG, Wu R, Dong ZR, Yang YF, Yan YC, et al. Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis. Frontiers in oncology. 2021;11:605648. Epub 2021/03/09. pmid:33680960; PubMed Central PMCID: PMC7933452.

43. Sun P, Dong X, Cheng X, Hu Q, Zheng Q. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. PloS one. 2014;9(7):e102761. Epub 2014/07/25. pmid:25058587; PubMed Central PMCID: PMC4109946.

44. Liu GM, Huang XY, Shen SL, Hu WJ, Peng BG. Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis. Hepatology research: the official journal of the Japan Society of Hepatology. 2016;46(1):100–10. Epub 2015/09/04. pmid:26331530.

45. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51(5):890–7. Epub 20090723. pmid:19747749.

46. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. Journal of hepatology. 2003;38(2):200–7. Epub 2003/01/28. pmid:12547409.

47. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89(3):500–7. Epub 2000/08/10. pmid:10931448.

48. Zheng J, Chou JF, Gönen M, Vachharajani N, Chapman WC, Majella Doyle MB, et al. Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort. Annals of surgery. 2017;266(4):693–701. Epub 2017/06/27. pmid:28650354; PubMed Central PMCID: PMC8404085.

49. Poon RT. Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol. 2009;16(4):792–4. Epub 20090204. pmid:19190964.

50. Ivanics T, Murillo Perez CF, Claasen M, Patel MS, Morgenshtern G, Erdman L, et al. Dynamic risk profiling of HCC recurrence after curative intent liver resection. Hepatology (Baltimore, Md). 2022;76(5):1291–301. Epub 2022/02/19. pmid:35178739.